$4.69
Value $371M
CRMD and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$4.69
Value $371M
$266.30
Value $642B
CorMedix (CRMD) has a market value of $371M and Johnson & Johnson (JNJ) $642B. Over the last year, with dividends, CRMD moved -53.4% and JNJ +36.1%. The P/E is 5.8 for CRMD and 39.9 for JNJ. Dividend yield: CRMD none, JNJ 1.98%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CRMD$371M
JNJ$642B
JNJ is 1,731 times CRMD
Revenue, 12 months
CRMD$412M
JNJ$99.3B
JNJ is 241 times CRMD
Net income, 12 months
CRMD$64M
JNJ$16.1B
JNJ is 252 times CRMD
Operating margin
CRMD38.6%
JNJ–
ROIC
CRMD27.3%
JNJ12.4%
14.9 points apart
P/E
CRMD5.8
JNJ39.9
JNJ is 6.9 times CRMD
Dividend yield
CRMD0.0%
JNJ2.0%
2.0 points apart
5-year return
CRMD-5.1%
JNJ+88.4%
93.5 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CRMD-5.1%
JNJ+88.4%
| Period | CRMDWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | -53.4%Price -53.4% | +36.1%Price +33.1% |
| 3 years since November 17, 2023 | +17.2%+5.4% a yearPrice +17.2% | +93.5%+24.6% a yearPrice +77.7% |
| 5 years since November 18, 2021 | -5.1%-1.0% a yearPrice -5.1% | +88.4%+13.5% a yearPrice +63.9% |
| 10 years since November 21, 2016 | -45.3%-5.9% a yearPrice -45.3% | +201.6%+11.7% a yearPrice +131.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CRMDCorMedixJNJJohnson & Johnson
| Price | $4.69 | $266.30 |
|---|---|---|
| Market value | $371M | $642B |
| Enterprise value (EV) | $16M | $669B |
| P/E | 5.8 | 39.9 |
| P/E, 5-year median | – | 21.9 |
| P/B | 0.8 | 7.9 |
| EV/EBIT | 0.1 | 37.7 |
| Free cash flow yield | 83.0% | 3.2% |
| Revenue, 12 months | $412M | $99.3B |
|---|---|---|
| Net income, 12 months | $64M | $16.1B |
| Free cash flow, 12 months | $308M | $20.6B |
| Earnings per share, 12 months | $0.81 | $6.59 |
| Revenue growth, year on year | 617.0% | 6.1% |
| Revenue growth a year, past | +319.8%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | 77.5% | 67.6% |
|---|---|---|
| Operating margin | 38.6% | – |
| Net margin | 15.5% | 16.2% |
| ROIC | 27.3% | 12.4% |
| ROE | 14.9% | 19.7% |
| Cash | $355M | $17.2B |
|---|---|---|
| Total debt | $144.6K | $44.7B |
| Net debt / EBITDA | -2.2 | 1.1 |
| Interest cover | 57.2× | 18.0× |
| Dividend yield | – | 2.0% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | – | 0.9% |
| Shareholder yield | – | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($642B) is about 1,731.0 times CorMedix ($371M), at today's prices.
Since November 21, 2016, CRMD's price moved -45.3% and JNJ's +131.4%. With dividends: CRMD -45.3% (-5.9% a year), JNJ +201.6% (+11.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for CorMedix and 1.98% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
At today's price, the P/E is 5.8 for CRMD and 39.9 for JNJ. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 15.5% for CorMedix and 16.2% for Johnson & Johnson, and the operating margin 38.6% and –. Revenue was $412M and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.